Literature DB >> 33073549

Ligand Density Controls C-Type Lectin-Like Molecule-1 Receptor-Specific Uptake of Polymer Nanoparticles.

Marian A Ackun-Farmmer1,2, Kharimat L Alatise1, Griffin Cross3, Danielle S W Benoit1,2,4,5.   

Abstract

The newest generation of drug delivery systems (DDSs) exploits ligands to mediate specific targeting of cells and/or tissues. However, studies investigating the link between ligand density and nanoparticle (NP) uptake are limited to a small number of ligand-receptor systems. C-type lectin-like molecule-1 (CLL1) is uniquely expressed on myeloid cells, which enables the development of receptors specifically targeting treat various diseases. This study aims to investigate how NPs with different CLL1 targeting peptide density impact cellular uptake. To this end, poly(styrene-alt-maleic anhydride)-b-poly(styrene) NPs are functionalized with cyclized CLL1 binding peptides (cCBP) ranging from 240 ± 12 to 31 000 ± 940 peptides per NP. Unexpectedly, the percentage of cells with internalized NPs is decreased for all cCBP-NP designs regardless of ligand density compared to unmodified NPs. Internalization through CLL1 receptor-mediated processes is further investigated without confounding the effects of NP size and surface charge. Interestingly, high density cCBP-NPs (>7000 cCBP per NP) uptake is dominated by CLL1 receptor-mediated processes while low density cCBP-NPs (≈200 cCBP per NP) and untargeted NP occurred through non-specific clathrin and caveolin-mediated endocytosis. Altogether, these studies show that ligand density and uptake mechanism should be carefully investigated for specific ligand-receptor systems for the design of targeted DDSs to achieve effective drug delivery.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  C-type lectin-like molecule-1 binding peptides; cell uptake; ligand density

Year:  2020        PMID: 33073549      PMCID: PMC7959326          DOI: 10.1002/adbi.202000172

Source DB:  PubMed          Journal:  Adv Biosyst        ISSN: 2366-7478


  50 in total

1.  Multivalency Effect of TAT-Peptide-Functionalized Nanoparticle in Cellular Endocytosis and Subcellular Trafficking.

Authors:  Chumki Dalal; Nikhil R Jana
Journal:  J Phys Chem B       Date:  2017-03-31       Impact factor: 2.991

2.  A fluorescence quenching technique using trypan blue to differentiate between attached and ingested glutaraldehyde-fixed red blood cells in phagocytosing murine macrophages.

Authors:  J D Loike; S C Silverstein
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

3.  Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production.

Authors:  Chang-Hung Chen; Helen Floyd; N Eric Olson; Dario Magaletti; Chang Li; Kevin Draves; Edward A Clark
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

4.  CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.

Authors:  Ying-Ping Jiang; Bob Y Liu; Quan Zheng; Swapna Panuganti; Ruoying Chen; Jianyu Zhu; Madhavi Mishra; Jianqing Huang; Trang Dao-Pick; Sharmili Roy; XiaoXian Zhao; Jeffrey Lin; Gautam Banik; Eric D Hsi; Ramkumar Mandalam; Jagath R Junutula
Journal:  Blood Adv       Date:  2018-07-24

5.  CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.

Authors:  Tim J A Hutten; Soley Thordardottir; Hanny Fredrix; Lisanne Janssen; Rob Woestenenk; Jurjen Tel; Ben Joosten; Alessandra Cambi; Mirjam H M Heemskerk; Gerben M Franssen; Otto C Boerman; Lex B H Bakker; Joop H Jansen; Nicolaas Schaap; Harry Dolstra; Willemijn Hobo
Journal:  J Immunol       Date:  2016-08-26       Impact factor: 5.422

6.  Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.

Authors:  Roland B Walter; Brian W Raden; Darren M Kamikura; Jonathan A Cooper; Irwin D Bernstein
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

7.  CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.

Authors:  Jinghua Wang; Siyu Chen; Wei Xiao; Wende Li; Liang Wang; Shuo Yang; Weida Wang; Liping Xu; Shuangye Liao; Wenjian Liu; Yang Wang; Nawei Liu; Jianeng Zhang; Xiaojun Xia; Tiebang Kang; Gong Chen; Xiuyu Cai; Han Yang; Xing Zhang; Yue Lu; Penghui Zhou
Journal:  J Hematol Oncol       Date:  2018-01-10       Impact factor: 17.388

8.  A mobile endocytic network connects clathrin-independent receptor endocytosis to recycling and promotes T cell activation.

Authors:  Ewoud B Compeer; Felix Kraus; Manuela Ecker; Gregory Redpath; Mayan Amiezer; Nils Rother; Philip R Nicovich; Natasha Kapoor-Kaushik; Qiji Deng; Guerric P B Samson; Zhengmin Yang; Jieqiong Lou; Michael Carnell; Haig Vartoukian; Katharina Gaus; Jérémie Rossy
Journal:  Nat Commun       Date:  2018-04-23       Impact factor: 14.919

Review 9.  Nanoparticles in the clinic: An update.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  Bioeng Transl Med       Date:  2019-09-05

Review 10.  Endocytic Recycling of MHC Class I Molecules in Non-professional Antigen Presenting and Dendritic Cells.

Authors:  Sebastian Montealegre; Peter M van Endert
Journal:  Front Immunol       Date:  2019-01-07       Impact factor: 7.561

View more
  3 in total

1.  Nanoparticle-Mediated Delivery of Micheliolide Analogs to Eliminate Leukemic Stem Cells in the Bone Marrow.

Authors:  Marian A Ackun-Farmmer; Hanan Alwaseem; Michele Counts; Andrew Bortz; Simone Giovani; Benjamin J Frisch; Rudi Fasan; Danielle S W Benoit
Journal:  Adv Ther (Weinh)       Date:  2021-10-08

Review 2.  Embracing nanomaterials' interactions with the innate immune system.

Authors:  Abraham J P Teunissen; Marianne E Burnett; Geoffrey Prévot; Emma D Klein; Daniel Bivona; Willem J M Mulder
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-04-13

3.  Macrophage depletion increases target specificity of bone-targeted nanoparticles.

Authors:  Marian A Ackun-Farmmer; Baixue Xiao; Maureen R Newman; Danielle S W Benoit
Journal:  J Biomed Mater Res A       Date:  2021-07-28       Impact factor: 4.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.